Market Cap | 36.80M | P/E | - | EPS this Y | 56.60% | Ern Qtrly Grth | - |
Income | -64.83M | Forward P/E | -1.29 | EPS next Y | 10.50% | 50D Avg Chg | 11.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -49.00% |
Dividend | N/A | Price/Book | 0.97 | EPS next 5Y | - | 52W High Chg | -86.00% |
Recommedations | 2.60 | Quick Ratio | 7.10 | Shares Outstanding | 33.15M | 52W Low Chg | 86.00% |
Insider Own | 10.43% | ROA | -49.62% | Shares Float | 15.20M | Beta | 0.10 |
Inst Own | 57.90% | ROE | -104.04% | Shares Shorted/Prior | 130.12K/149.87K | Price | 1.10 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 1,161,178 | Target Price | 2.00 |
Oper. Margin | - | Earnings Date | Aug 7 | Volume | 1,826,389 | Change | 0.00% |
Satsuma Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops novel therapeutic products for the acute treatment of migraines. The company's product candidature includes STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. As of June 8, 2023, Satsuma Pharmaceuticals, Inc. operates as a subsidiary of Shin Nippon Biomedical Laboratories, Ltd.
HC Wainwright & Co. | Neutral | Apr 18, 23 |
Mizuho | Neutral | Mar 30, 23 |
HC Wainwright & Co. | Buy | Mar 30, 23 |
Mizuho | Neutral | Nov 15, 22 |
HC Wainwright & Co. | Buy | Nov 15, 22 |
SVB Leerink | Market Perform | Nov 15, 22 |
SVB Leerink | Outperform | Oct 10, 22 |
HC Wainwright & Co. | Buy | Sep 21, 22 |
Ladenburg Thalmann | Buy | Aug 31, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Leonard Braden Michael | 10% Owner 10% Owner | Nov 21 | Buy | 0.7116 | 150,000 | 106,740 | 150,000 | 11/23/22 |